Sign up to access all valuation multiples
PeptiDream Inc is a biopharmaceutical company, engaged in the research and development of new pharmaceutical candidates. It discovers constrained peptides, small molecules, and peptide-drug conjugate therapeutics using its Peptide Discovery Platform System. The company aspires to be a leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide.
2006
83
LTM Revenue $316M
LTM EBITDA $147M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PeptiDream has a last 12-month revenue (LTM) of $316M and a last 12-month EBITDA of $147M.
In the most recent fiscal year, PeptiDream achieved revenue of $315M and an EBITDA of $160M.
PeptiDream expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PeptiDream valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $316M | XXX | $315M | XXX | XXX | XXX |
| Gross Profit | $232M | XXX | $232M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | $147M | XXX | $160M | XXX | XXX | XXX |
| EBITDA Margin | 47% | XXX | 51% | XXX | XXX | XXX |
| EBIT | $139M | XXX | $142M | XXX | XXX | XXX |
| EBIT Margin | 44% | XXX | 45% | XXX | XXX | XXX |
| Net Profit | $114M | XXX | $101M | XXX | XXX | XXX |
| Net Margin | 36% | XXX | 32% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, PeptiDream's stock price is JPY 1500 (or $10).
PeptiDream has current market cap of JPY 194B (or $1.3B), and EV of JPY 179B (or $1.2B).
See PeptiDream trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.3B | XXX | XXX | XXX | XXX | $0.75 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, PeptiDream has market cap of $1.3B and EV of $1.2B.
PeptiDream's trades at 3.8x EV/Revenue multiple, and 7.5x EV/EBITDA.
Equity research analysts estimate PeptiDream's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PeptiDream has a P/E ratio of 11.5x.
See valuation multiples for PeptiDream and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | 8.2x | XXX | 7.5x | XXX | XXX | XXX |
| EV/EBIT | 8.7x | XXX | 8.5x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 11.5x | XXX | 12.9x | XXX | XXX | XXX |
| EV/FCF | 10.2x | XXX | 8.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPeptiDream's last 12 month revenue growth is 2%
PeptiDream's revenue per employee in the last FY averaged $3.8M, while opex per employee averaged $1.1M for the same period.
PeptiDream's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PeptiDream's rule of X is 51% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for PeptiDream and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 47% | XXX | 51% | XXX | XXX | XXX |
| EBITDA Growth | -10% | XXX | 53% | XXX | XXX | XXX |
| Rule of 40 | 33% | XXX | 53% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 51% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $3.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PeptiDream acquired XXX companies to date.
Last acquisition by PeptiDream was XXXXXXXX, XXXXX XXXXX XXXXXX . PeptiDream acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was PeptiDream founded? | PeptiDream was founded in 2006. |
| Where is PeptiDream headquartered? | PeptiDream is headquartered in Japan. |
| How many employees does PeptiDream have? | As of today, PeptiDream has 83 employees. |
| Who is the CEO of PeptiDream? | PeptiDream's CEO is Mr. Patrick C. Reid. |
| Is PeptiDream publicy listed? | Yes, PeptiDream is a public company listed on TKS. |
| What is the stock symbol of PeptiDream? | PeptiDream trades under 4587 ticker. |
| When did PeptiDream go public? | PeptiDream went public in 2013. |
| Who are competitors of PeptiDream? | Similar companies to PeptiDream include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of PeptiDream? | PeptiDream's current market cap is $1.3B |
| What is the current revenue of PeptiDream? | PeptiDream's last 12 months revenue is $316M. |
| What is the current revenue growth of PeptiDream? | PeptiDream revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of PeptiDream? | Current revenue multiple of PeptiDream is 3.8x. |
| Is PeptiDream profitable? | Yes, PeptiDream is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of PeptiDream? | PeptiDream's last 12 months EBITDA is $147M. |
| What is PeptiDream's EBITDA margin? | PeptiDream's last 12 months EBITDA margin is 47%. |
| What is the current EV/EBITDA multiple of PeptiDream? | Current EBITDA multiple of PeptiDream is 8.2x. |
| What is the current FCF of PeptiDream? | PeptiDream's last 12 months FCF is $118M. |
| What is PeptiDream's FCF margin? | PeptiDream's last 12 months FCF margin is 37%. |
| What is the current EV/FCF multiple of PeptiDream? | Current FCF multiple of PeptiDream is 10.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
